BMI View: As Norway's economy continues to rebalance away from oil dependence, industrial policy
aimed at boosting production capacity and research in the health sector is set to strengthen. In fact,
Norway's government has identified the life sciences and biomedica ..."
BMI View: Although we see limited chances for Portugal to improve its competitiveness in order to attract
foreign investment in the near future, rising private consumption and fiscal policy will support
pharmaceutical and healthcare market growth rates over a multi- ..."
BMI View: The Slovakian pharmaceutical market will remain one of the most attractive markets in CEE.
While the authorities continue to impose stringent pricing controls, limiting patented medicine access, there
is clear motivation to widen innovative drug access to ..."
BMI View: Continued political instability coupled with a bleak economic outlook will continue to repress
the pharmaceutical and healthcare sectors in Croatia. Necessary austerity measures will impose further
barriers towards growth and reduce the use of high-value pat ..."
BMI View: The Hungarian government's fiscal stimulus initiatives will boost the private consumption of
pharmaceuticals, particularly the over the counter medicines segment. A secondary set of initiatives are
aimed at increasing domestic production capabilities, such a ..."
BMI View: The Irish government's four-year agreement with the pharmaceutical industry with regard to
drug pricing reflects the government's continued focus on cost control measures targeting pharmaceutical
expenditure. The agreed price-reduction mechanism for existing ..."
BMI View: Serbia will remain an unattractive market for multinational drugmakers in comparison to its
regional neighbours. Government cost-containment, via severe drug price cuts, and continued economic
issues will dampen the country's growth outlook.
Headline E ..."
BMI View: Declining government reimbursement for prescription medicines and the promotion of lowervalue
generic medicines does not bode well for innovative drugmakers selling their products in Sweden,
particularly as the government is the primary purchaser of pharmace ..."
BMI View: Switzerland will remain amongst the wealthiest countries in the world in real GDP per capita
terms, which together with an aging population and a preference for patented medicines, will keep
pharmaceutical spending high. However, faced with growing healthcar ..."
BMI View: Germany's large and expanding pharmaceutical market will continue to generate commercial
opportunities for drugmakers over the forecast period. While Germany's ongoing economic rebalancing
will continue to support robust domestic consumption indices, includi ..."